Edition:
India

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

5.66USD
1:30am IST
Change (% chg)

$-0.28 (-4.71%)
Prev Close
$5.94
Open
$5.92
Day's High
$5.92
Day's Low
$5.58
Volume
30,766
Avg. Vol
63,307
52-wk High
$13.03
52-wk Low
$4.31

Latest Key Developments (Source: Significant Developments)

Aldeyra Therapeutics Q2 Loss Per Share $0.49
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.49.Q2 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.PART 1 OF ADAPTIVE PHASE 3 RENEW TRIAL IN DRY EYE DISEASE EXPECTED TO BE COMPLETED IN Q4 2019.MEETING WITH FDA SCHEDULED IN Q4 2019 TO CONFIRM DESIGN OF SECOND PHASE 3 TRIAL IN ALLERGIC CONJUNCTIVITIS.INITIATION OF ADAPTIVE PHASE 3 GUARD TRIAL OF ADX-2191 IN PROLIFERATIVE VITREORETINOPATHY PLANNED FOR Q4 2019.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $69.5 MILLION AS OF JUNE 30, 2019.  Full Article

Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES RESULTS FROM THE SOLACE TRIAL IN NONINFECTIOUS ANTERIOR UVEITIS.ALDEYRA THERAPEUTICS INC - COMPANY PLANS TO PRIORITIZE PHASE 3 OCULAR PIPELINE PROGRAMS IN DRY EYE DISEASE, ALLERGIC CONJUNCTIVITIS, AND PROLIFERATIVE VITREORETINOPATHY.ALDEYRA THERAPEUTICS INC - STATISTICAL SIGNIFICANCE NOT ACHIEVED FOR PRIMARY OR SECONDARY ENDPOINTS.ALDEYRA THERAPEUTICS INC - NONINFECTIOUS ANTERIOR UVEITIS PROGRAM TO BE DISCONTINUED.  Full Article

Aldeyra Therapeutics Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.58.Q1 EARNINGS PER SHARE ESTIMATE $-0.43 -- REFINITIV IBES DATA.  Full Article

Aldeyra Therapeutics Eye Drug Meets Main and Key Secondary Goals In Late-Stage Trial
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 ALLEVIATE TRIAL IN PATIENTS WITH ALLERGIC CONJUNCTIVITIS.ALDEYRA THERAPEUTICS INC - CLINICAL TRIAL MET PRIMARY ENDPOINT AND KEY SECONDARY ENDPOINT FOR BOTH CONCENTRATIONS OF REPROXALAP..ALDEYRA THERAPEUTICS - ENTERED LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL THAT PROVIDES UP TO $60 MILLION IN NON-DILUTIVE FINANCING.ALDEYRA SAYSS CONDUCTING CLINICAL METHOD DEVELOPMENT STUDIES TO ASSESS FEASIBILITY OF MEASURING OCULAR ITCHING INDUCED BY ENVIRONMENTAL EXPOSURE TO ALLERGEN.ALDEYRA THERAPEUTICS - IN H2, PLANS TO MEET TO DISCUSS ALLEVIATE RESULTS AND REMAINING CLINICAL REQUIREMENTS FOR POTENTIAL SUBMISSION OF NDA TO FDA.ALDEYRA THERAPEUTICS INC - COMPANY CLOSED ON $60 MILLION TERM LOAN FACILITY.  Full Article

Aldeyra Therapeutics Q3 Loss Per Share $0.52
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.52.Q3 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $35.1 MILLION AS OF SEPTEMBER 30, 2018.IN OCTOBER 2018, $67.6 MILLION OF NET PROCEEDS WAS RAISED, OPERATIONS EXPECTED TO BE FUNDED THROUGH 2020.  Full Article

Aldeyra Therapeutics Announces Proposed Public Offering Of Common Stock
Thursday, 27 Sep 2018 

Sept 26 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ALDEYRA THERAPEUTICS INC SAYS INTENDS TO OFFER AND SELL, SUBJECT TO MARKET AND OTHER CONDITIONS, 5,250,000 SHARES OF ITS COMMON STOCK.  Full Article

Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES.ALDEYRA THERAPEUTICS INC - ‍ ENTERED INTO A COLLABORATIVE RESEARCH AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT​.ALDEYRA - ‍ AGREEMENT WITH JANSSEN TO ADVANCE DEVELOPMENT OF EXISTING ANALOGS OF REPROXALAP FOR TREATMENT OF SYSTEMIC INFLAMMATORY DISEASES​.ALDEYRA THERAPEUTICS INC - WILL COLLABORATE WITH JANSSEN ON RESEARCH ACTIVITIES, WHICH WILL BE GOVERNED BY A JOINT SCIENTIFIC REVIEW COMMITTEE​.ALDEYRA - ‍ FOR A LIMITED PERIOD, SUBJECT TO CONDITIONS, JANSSEN TO RETAIN OPTION TO NEGOTIATE EXCLUSIVE LICENSE PERTAINING TO COMPOUNDS DEVELOPED.  Full Article

Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING.  Full Article

Aldeyra Therapeutics reports Q3 loss per share of $0.32
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.32.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.‍Cash, cash equivalents, and marketable securities were $47.9 million as of September 30, 2017​.  Full Article